Kris Todd, MS

Eli Lilly and Company

Poster(s):

• P3546 - Safety, Tolerability, and Pharmacokinetics of Mirikizumab in Chinese Healthy Subjects: Results from a Phase 1 Study
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT